Saudi Arabia is expanding its ambitions in advanced therapies through Vision 2030, focusing on building local biomanufacturing capabilities and accelerating access to cell and gene therapies.

This discussion examines how next‑gen platforms and predictive modelling approaches provide the process insight to drive consistency, yield, and potency as programs move towards commercialization.

US biotech companies expanding clinical trials into the EU and UK face complex regulatory and logistics challenges. Damian Larington shares key requirements, common mistakes and emerging trial trends.

One of the biggest hurdles sponsors face is finding a CDMO with true commercial AAV experience—partners who have successfully taken them through global approvals into the commercial market.

Limula is addressing the challenges of clinical centres and biotech companies looking for a solution enabling fully automated production of cell therapies at the point-of-care.

NKILT Therapeutics brings a novel off-the-shelf cell therapy to tackle over half of cancers across hematologic and solid tumors.